TRICLIP™ TRICUSPID VALVE REPAIR CLINICAL DATA
Built upon a proven clip-based platform, TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.
TRICLIP™ TRICUSPID VALVE REPAIR CLINICAL DATA
Built upon a proven clip-based platform, TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.
OUTCOMES IN REAL-WORLD STUDIES3
THE FUTURE IS bRIGHT
bRIGHT real-world study initial 30-day results
Proven in the largest and first Tricuspid TEER real-world study to date, the bRIGHT study demonstrates that TriClip™ TEER significantly reduces TR with tailored therapy across a broad range of patient anatomies, resulting in meaningful clinical outcomes in a safe and effective procedure.
98%
IMPLANT
SUCCESS
91%
ACUTE PROCEDURAL
SUCCESS
0.3%
ALL-CAUSE
MORTALITY
0.3%
STROKE
0%
EMBOLIZATION
- Significant TR reduction at 30 days3
- Strong real-world clinical outcomes at 30 days3
18 Points significant improvement in KCCQ-OS health-related quality of life - TriClip TEER continues to demonstrate3
HIGH PROCEDURAL
SUCCESS98%
Implant
sucess rateSHORT
DEVICE TIME
78±41
Minutes
HIGH SAFETY
PROFILE
99%
Freedom
from MAEs
99.7% survival1.3% reintervention
0% embolization
TRILUMINATE™ CLINICAL TRIAL
Proven safety and effectiveness
93%
SURVIVAL
AT 1 YR2
100%
IMPLANT
SUCCESS4
91%
ACUTE PROCEDURAL
SUCCESS RATE4
0%
STROKE4
0%
CONVERSION TO
SURGERY4
- Significant and Durable TR Reduction2
Durable reduction in tricuspid regurgitation (TR)
- Significant improvement in function and quality of life2
Durable improvements in NYHA
20 Points significant improvement in KCCQ-OS health-related quality of life at one-year - TriClip TEER demonstrates high safety profile2
High survival in a
fragile patient population93%
Survival
at 1 yearLow rates of
major adverse events93%
Freedom from MAEs
at 1 year - Significant reduction in hospitalizations2
Reduced hospitalization rate
MAT-2006556 v7.0 | Item approved for Global OUS use only.